Annual General Meeting on May 25, 2022 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review

GenSight Biologics Reports Full Year 2021 Consolidated Financial Results

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

GenSight Biologics Announces its 2022 Financial Calendar

GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe

GenSight Biologics reports clinically meaningful vision improvement is maintained 4 years after one-time treatment with LUMEVOQ® gene therapy